What is new in mediastinal staging?
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
medline:
6
12
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Appropriate staging is of utmost importance in nonsmall cell lung cancer (NSCLC), as the pathologic stage dictates both overall prognosis and appropriate therapeutic pathways. This article seeks to review the current recommendations for mediastinal staging of NSCLC and available modalities to achieve this. Landmark publications pertaining to recent advancements in NSCLC treatments are also highlighted and the role of specific bronchoscopic modalities for tissue acquisition are reviewed. Recent advancements in the treatment of NSCLC have made accurate mediastinal staging more important than ever. Guidelines and recommendations outlining patients that warrant invasive mediastinal staging are available and a systematic approach should be utilized when sampling is performed. Ensuring the adequacy of tissue for the growing number of molecular biomarkers that must be tested has been the focus of many recent studies. Appropriate mediastinal staging is crucial for the management of patients with NSCLC as is obtaining adequate tissue for diagnostic and therapeutic purposes. EBUS-TBNA is sufficient for the diagnosis of nonsmall cell and small cell lung carcinomas, but EBUS-guided intranodal forceps and cryobiopsy may provide more optimal specimen for patients with benign disease, such as sarcoidosis, or in cases of lymphoma. Further studies are necessary to better delineate the role of these techniques in the diagnosis and staging of mediastinal diseases before they become the primary diagnostic modalities.
Identifiants
pubmed: 37851368
doi: 10.1097/MCP.0000000000001022
pii: 00063198-990000000-00116
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-34Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Sung H, Ferlay J, Siegal RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249.
National Comprehensive Cancer Network (NCCN). NCCN Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2023.: https://www.Nccn.Org/Professionals/Physician_gls/Pdf/Nsclc.Pdf [Accessed 24 August 2023]
Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest 2017; 151:193–203.
Asamura H, Chansky K, Crowley J, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10:1675–1684.
Lucena CM, Martin-Deleon R, Boada M, et al. Integral mediastinal staging in patients with Nonsmall cell lung cancer and risk factors for occult N2 disease. Respir Med 2023; 208:107–132.
Merritt RE, Abdel-Rasoul M, D'Souza DM, Kneuertz PJ. Lymph node upstaging for robotic, thoracoscopic, and open lobectomy for stage T2-3N0 lung cancer. Ann Thorac Surg 2023; 115:175–182.
Dezube AR, Mazzola E, Deeb A, et al. Mandatory nodal evaluation during resection of clinical T1a non-small cell lung cancers. Ann Thorac Surg 2022; 113:1583–1590.
Tan KS, Hsu M, Adusumilli PS. Pathologic node-negative lung cancer: adequacy of lymph node yield and a tool to assess the risk of occult nodal disease. Lung Cancer 2022; 174:60–66.
Altorki N, Wang X, Kozono D, et al. Lobar or sublobar resection for peripheral Stage IA non-small-cell lung cancer. N Engl J Med 2023; 388:489–498.
Felip E, Altorki N, Zhou C, et al. IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA nonsmall-cell lung cancer (IMpower010): a randomized, multicenter, open-label, phase 3 trial. Lancet 2021; 398:1344–1357.
Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated Stage IB-IIIA non-small-cell lung cancer: updated results from the Phase III Randomized ADAURA Trial. J Clin Oncol 2023; 41:1830–1840.
Forde PM, Spicer J, Lu S, et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386:1973–1985.
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. J Clin Oncol 2022; 40:1301–1311.
Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging nonsmall cell lung cancer: diagnosis and management of lung cancer, 3 rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST 2013; 143: (5 Suppl): e211S–e250S.
Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009; 151:221–228. W-48.
Darling GE, Maziak DE, Inculet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in nonsmall cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011; 6:1367–1372.
Wahidi MM, Herth F, Yasufuku K, et al. Technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration: CHEST guideline and expert panel report. Chest 2016; 149:816–835.
Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg 2011; 142:1393–1400. e1.
Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006; 130:710–718.
Herth FJ, Eberhardt R, Krasnik M, et al. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008; 133:887–891.
Al-Sarraf N, Gately K, Lucey J, et al. Lymph node staging by means of positron emission tomography is less accurate in nonsmall cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer 2008; 60:62–68.
De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for nonsmall-cell lung cancer. Eur J Cardiothorac Surg 2014; 45:787–798.
Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. Eur Respir J 2015; 46:40–60.
Hishida T, Yoshida J, Nishimura M, et al. Problems in the current diagnostic standards of clinical N2 nonsmall cell lung cancer. Thorax 2008; 63:526–531.
Gómez-Caro A, Boada M, Cabanas M, et al. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage nonsmall-cell lung cancer. Eur J Cardiothorac Surg 2012; 41:93–100.
Lee PC, Port JL, Korst RJ, et al. Risk factors for occult mediastinal metastases in clinical stage I nonsmall cell lung cancer. Ann Thorac Surg 2007; 84:177–181.
Chen K, Yang F, jiang G, et al. Development and validation of a clinical prediction model for N2 lymph node metastasis in nonsmall cell lung cancer. Ann Thorac Surg 2013; 96:1761–1768.
DuComb EA, Tonelli BA, Tuo Y, et al. Evidence for expanding invasive mediastinal staging for peripheral T1 lung tumors. Chest 2020; 158:2192–2199.
Kennedy WR, Samson PP, Gabani P, et al. Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC. Radiother Oncol 2020; 150:206–210.
Mullins BT, Moore DT, Rivera MP, et al. The impact of pathologic staging of the hilar/mediastinal nodes on outcomes in patients with early-stage NSCLC receiving stereotactic body radiotherapy. J Thorac Dis 2021; 13:1045–1054.
Sanz-Santos J, Serra P, Torky M, et al. Systematic compared with targeted staging with endobronchial ultrasound in patients with lung cancer. Ann Thorac Surg 2018; 106:398–403.
Crombag LMM, Dooms C, Stigt JA, et al. Systematic and combined endosonographic staging of lung cancer (SCORE study). Eur Respir J 2019; 53:1800800.
Cole AJ, Hardcastle N, Turgeon G-A, et al. Systematic endobronchial ultrasound-guided transbronchial needle aspiration improves radiotherapy planning in nonsmall cell lung cancer. ERJ Open Res 2019; 5:00004–2019.
Hylton DA, Kidane B, Spicer J, et al. Endobronchial ultrasound staging of operable nonsmall cell lung cancer: do triple-normal lymph nodes require routine biopsy? Chest 2021; 159:2470–2476.
Sullivan KA, Farrokhyar F, Leontiadis GI, et al. Routine systematic sampling versus targeted sampling during endobronchial ultrasound: a randomized feasibility trial. J Thorac Cardiovasc Surg 2022; 164:254–261. e1.
Serra P, Centeno C, Sanz-Santos J, et al. Is it necessary to sampled the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 /N1 on PET-CT? Lung Cancer 2020; 142:9–12.
Sainz Zúñiga PV, Martinez-Zayas G, Molina S, et al. Is biopsy of contralateral hilar N3 lymph nodes with negative PET-CT scan findings necessary when performing endobronchial ultrasound staging? Chest 2021; 159:1642–1651.
Casal RF, Lazarus DR, Kuhl K, et al. Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration under general anesthesia versus moderate sedation. Am J Respir Crit Care Med 2015; 191:796–803.
Zhang R, Ying K, Shi L, et al. Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a meta-analysis. Eur J Cancer 2013; 49:1860–1867.
Korevaar DA, Crombag LM, Cohen J, et al. Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis. Lancet Respir Med 2016; 4:960–968.
Ng J, Chan HP, Kee A, et al. Transitioning to combined EBUS EUS-B FNA for experienced EBUS bronchoscopist. Diagnostics (Basel) 2021; 11:1021.
Torii A, Oki M, Yamada A, et al. EUS-B-FNA enhances the diagnostic yield of EBUS bronchoscope for intrathoracic lesions. Lung 2022; 200:643–648.
Chrysikos S, Gkiozos I, Dimakou K, et al. Clinical utility of thoracic endosonography (EBUS/EUS-b) in mediastinal staging of patients with nonsmall cell lung cancer: comparison with integrated PET/CT - a real-life prospective study in Greece. J Thorac Dis 2020; 12:5657–5666.
Evinson M, Edwards T, Balata H, et al. Prevalence of nodal metastases in lymph node stations 8 & 8 in a large UK lung cancer surgical centre without routine preoperative EUS nodal stating. Lung Cancer 2018; 115:127–130.
Pickering EM, Holden VK, Heath JE, et al. Tissue acquisition during EBUS-TBNA: comparison of cell blocks obtained from a 19G versus 21G needle. J Bronchology Interv Pulmonol 2019; 26:237–244.
Kinoshita T, Ujiie H, Schwock J, et al. Clinical evaluation of the utility of a flexible 19-gauge EBUS-TBNA needle. J Thoracic Dis 2018; 10:2388–2396.
Wolters C, Darwiche K, Franzen D, et al. A prospective, randomized trial for the comparison of 19-G and 22-G endobronchial ultrasound-guided transbronchial aspiration needles; introducing a novel end point of sample weight corrected for blood content. Clin Lung Cancer 2019; 20:e265–e273.
Chaddha U, Ronaghi R, Elatre W, et al. Comparison of sample adequacy and diagnostic yield of 19- and 22-G EBUS-TBNA needles. J Bronchology Interv Pulmonol 2018; 25:264–268. 10.
Garrison G, Leclair T, Balla A, et al. Use of an additional 19-G EBUS-TBNA needle increases the diagnostic yield of EBUS-TBNA. J Bronchology Interv Pulmonol 2018; 25:269–273.
Dooms C, Vander Borght S, Yserbyt J, et al. A randomized clinical trial of Flex 19G needles versus 22G needles for endobronchial ultrasonography in suspected lung cancer. Respiration 2018; 96:275–282.
Guarize J, Diotti C, Casiraghi M, Donghi S, et al. Diagnostic performance and cell count of EBUS-TBNA needle gauges: a prospective trial. J Clin Med 2023; 12:4033.
Romatowski NPJ, Gillson AM, Stollery D, et al. Endobronchial ultrasound transbronchial needle aspiration with 19-gauge needle vs 21- and 22-gauge needles for mediastinal lymphadenopathy. Chest 2022; 162:712–720.
Agarwal A, Ghori U, Chaddha U, Murgu S. Combined EBUS-IFB and EBUS-TBNA vs. EBUS-TBNA alone for intrathoracic adenopathy: a meta-analysis. Ann Thorac Surg 2022; 114:340–348.
Lachkar S, Faur Q, Marguet F, et al. Assessment of endobronchial ultrasound-guided bronchoscopy (EBUS) intranodal forceps biopsy added to EBUS 19-gauge transbronchial needle aspiration: a blinded pathology panel analysis. Thorac Cancer 2023; 14:2149–2157.
Chrissian A, Misselhorn D, Chen A. Endobronchial-ultrasound guided miniforceps biopsy of mediastinal and hilar lesions. Ann Thorac Surg 2011; 92:284–288.
Herth FJ, Morgan RK, Eberhardt R, Ernst A. Endobronchial ultrasound-guided miniforceps biopsy in the biopsy of subcarinal masses in patients with low likelihood of nonsmall cell lung cancer. Ann Thorac Surg 2008; 85:1874–1878.
Ray AS, Li C, Murphy TE, et al. Improved diagnostic yield and specimen quality with EBUS-guided forceps biopsies: a retrospective analysis. Ann Thorac Surg 2020; 109:894–901.
Franke KJ, Bruckner C, Szyrach M, et al. The contribution of endobronchial ultrasound-guided forceps biopsy in the diagnostic workup of unexplained mediastinal and hilar lymphadenopathy. Lung 2012; 190:227–232.
Bramley K, Pisani MA, Murphy TE, et al. Endobronchial ultrasound-guided cautery-assisted transbronchial forceps biopsies: safety and sensitivity relative to transbronchial needle aspiration. Ann Thorac Surg 2016; 101:1870–1876.
Zhang J, Guo JR, Huang ZS, et al. Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomized trial. Eur Respir J 2021; 58:2100055.
Fan Y, Zhang AM, Wu XL, et al. Transbronchial needle aspiration combined with cryobiopsy in the diagnosis of mediastinal diseases: a multicenter, open-label randomized trial. Lancet Respir Med 2023; 11:256–264.
Ariza-Prota M, Pérez-Pallarés J, Fernández-Fernández A, et al. Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: safety, feasibility and diagnostic yield - experience in 50 cases. ERJ Open Res 2023; 9:448–2022.
Gershman E, Ikan AA, Pertzov B, et al. Mediastinal ‘deep freeze’ - transcarinal lymph node cryobiopsy. Thorac Cancer 2022; 13:1592–1596.
Maturu VN, Prasad VP, Vaddepally CR, et al. Endobronchial ultrasound-guided mediastinal lymph nodal cryobiopsy in patients with nondiagnostic/inadequate rapid on-site evaluation: a new step in the diagnostic algorithm. J Bronchol Intervent Pulmonol 2023; 00:000–000.
Oikonomidou R, Petridis D, Kosmidis C, Sapalidis K, et al. Cryo-Biopsy versus 19G needle versus 22G needle with EBUS-TBNA endoscopy. J Cancer 2022; 13:3084–3090.
Zhang J, Fu WL, Huang ZS, et al. Primary mediastinal seminoma achieved by transbronchial mediastinal cryobiopsy. Respiration 2020; 99:426–430.